SK16082000A3 - Ľudský bmp-7 promótor a spôsob výskumu substancií ovplyvňujúcich kosť pri použití tohto promótora - Google Patents
Ľudský bmp-7 promótor a spôsob výskumu substancií ovplyvňujúcich kosť pri použití tohto promótora Download PDFInfo
- Publication number
- SK16082000A3 SK16082000A3 SK1608-2000A SK16082000A SK16082000A3 SK 16082000 A3 SK16082000 A3 SK 16082000A3 SK 16082000 A SK16082000 A SK 16082000A SK 16082000 A3 SK16082000 A3 SK 16082000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- bone
- vector
- dna
- human
- human bmp
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000000126 substance Substances 0.000 title claims description 31
- 210000000988 bone and bone Anatomy 0.000 title abstract description 17
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 title 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims abstract description 27
- 239000013598 vector Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 16
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 15
- 208000017169 kidney disease Diseases 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 239000013604 expression vector Substances 0.000 claims description 21
- 238000003259 recombinant expression Methods 0.000 claims description 21
- 108060001084 Luciferase Proteins 0.000 claims description 9
- 239000005089 Luciferase Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000011164 ossification Effects 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 102000046107 human BMP7 Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 11
- 150000003384 small molecules Chemical class 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 210000000845 cartilage Anatomy 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 210000004102 animal cell Anatomy 0.000 abstract description 5
- 230000001002 morphogenetic effect Effects 0.000 abstract description 5
- 238000011144 upstream manufacturing Methods 0.000 abstract description 5
- 208000020084 Bone disease Diseases 0.000 abstract description 4
- 208000015100 cartilage disease Diseases 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 22
- 101100165559 Homo sapiens BMP7 gene Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 6
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000046148 human BMP4 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000762365 Mus musculus Bone morphogenetic protein 2 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000007355 cartilage morphogenesis Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- -1 small molecule organic compounds Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10120174A JPH11313675A (ja) | 1998-04-30 | 1998-04-30 | ヒトｂｍｐ−７プロモーターおよびこれを用いた骨関連物質の探索法 |
| PCT/IB1999/000733 WO1999057293A1 (en) | 1998-04-30 | 1999-04-22 | Human bmp-7 promoter and method for exploring bone-related substance by using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK16082000A3 true SK16082000A3 (sk) | 2001-05-10 |
Family
ID=14779761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1608-2000A SK16082000A3 (sk) | 1998-04-30 | 1999-04-22 | Ľudský bmp-7 promótor a spôsob výskumu substancií ovplyvňujúcich kosť pri použití tohto promótora |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6534268B1 (et) |
| EP (1) | EP1076713A1 (et) |
| JP (1) | JPH11313675A (et) |
| KR (1) | KR20010071193A (et) |
| CN (1) | CN1170941C (et) |
| AP (1) | AP1329A (et) |
| AU (1) | AU769124B2 (et) |
| BG (1) | BG64780B1 (et) |
| BR (1) | BR9910585A (et) |
| CA (1) | CA2326957A1 (et) |
| EA (1) | EA004509B1 (et) |
| EE (1) | EE200000627A (et) |
| GE (1) | GEP20033056B (et) |
| HR (1) | HRP20000736A2 (et) |
| HU (1) | HUP0102329A3 (et) |
| ID (1) | ID26704A (et) |
| IL (1) | IL139100A0 (et) |
| NO (1) | NO20005433L (et) |
| NZ (1) | NZ507625A (et) |
| PL (1) | PL343817A1 (et) |
| SK (1) | SK16082000A3 (et) |
| TR (1) | TR200003182T2 (et) |
| UA (1) | UA72212C2 (et) |
| WO (1) | WO1999057293A1 (et) |
| YU (1) | YU64900A (et) |
| ZA (1) | ZA200006080B (et) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US20070015701A1 (en) * | 2005-06-01 | 2007-01-18 | Samuel Zalipsky | Macromolecular conjugates of bone morphogenetic protein-7 |
| WO2008045498A1 (en) * | 2006-10-12 | 2008-04-17 | Ethicon, Inc. | Kidney-derived cells and methods of use in tissue repair and regeneration |
| WO2009139525A1 (en) * | 2008-05-16 | 2009-11-19 | Industry Foundation Of Chonnam National University | An synthetic peptide containing bone forming peptide 1(bfp 1) for stimulating osteoblast differentiation, and pharmaceutical composition comprising the synthetic peptide |
| CA2799786A1 (en) | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Non-fouling, anti-microbial, anti-thrombogenic graft compositions |
| AU2011264834B2 (en) | 2010-06-09 | 2015-03-12 | Semprus Biosciences Corp. | Non-fouling, anti-microbial, anti-thrombogenic graft-from compositions |
| WO2011156596A2 (en) | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Articles having non-fouling surfaces and processes for preparing the same including pretreatment of substrates |
| WO2012024489A2 (en) | 2010-08-18 | 2012-02-23 | Emory University | Compounds and compositions for ossification and methods related thereto |
| US11179500B2 (en) | 2011-02-24 | 2021-11-23 | Emory University | JAB1 inhibitory compositions for ossification and methods related thereto |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| CA2859195C (en) | 2011-12-14 | 2016-09-27 | Semprus Biosciences Corp. | Imbibing process for contact lens surface modification |
| CA2858730C (en) | 2011-12-14 | 2017-07-18 | Semprus Biosciences Corp. | Surface modified contact lenses |
| US9000063B2 (en) | 2011-12-14 | 2015-04-07 | Semprus Biosciences Corporation | Multistep UV process to create surface modified contact lenses |
| US9120119B2 (en) | 2011-12-14 | 2015-09-01 | Semprus Biosciences Corporation | Redox processes for contact lens modification |
| WO2013090790A1 (en) | 2011-12-14 | 2013-06-20 | Semprus Biosciences Corp. | Silicone hydrogel contact lens modified using lanthanide or transition metal oxidants |
| WO2019005563A1 (en) * | 2017-06-27 | 2019-01-03 | St. Jude Children's Research Hospital | METHODS ASSOCIATED WITH THE ACTIVATION OF THE SIGNALING PATHWAY OF BONE MORPHOGENETIC PROTEINS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| DK0429570T3 (da) | 1989-03-28 | 1998-04-27 | Genetics Inst | Osteoinducerende præparater |
| US5650276A (en) * | 1991-03-11 | 1997-07-22 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
| WO1993003382A2 (en) * | 1991-08-01 | 1993-02-18 | Pharmaceutical Discovery Corporation | Characterization of specific drug receptors with fluorescent ligands |
| CA2191583C (en) * | 1994-06-07 | 2007-03-27 | Engin Ozkaynak | Methods and compositions for modulating morphogenic protein expression |
| US6083690A (en) * | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
| EP0937145A1 (en) | 1996-11-22 | 1999-08-25 | Akzo Nobel N.V. | Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis |
| US5863790A (en) | 1997-05-14 | 1999-01-26 | Minnesota Mining And Manfacturing Company | Biological sterility indicator |
| CA2291510A1 (en) * | 1997-05-29 | 1998-12-03 | Curis, Inc. | Modulators of morphogen expression and methods of identifying the same |
-
1998
- 1998-04-30 JP JP10120174A patent/JPH11313675A/ja active Pending
-
1999
- 1999-04-22 CA CA002326957A patent/CA2326957A1/en not_active Abandoned
- 1999-04-22 HU HU0102329A patent/HUP0102329A3/hu unknown
- 1999-04-22 EE EEP200000627A patent/EE200000627A/et unknown
- 1999-04-22 IL IL13910099A patent/IL139100A0/xx unknown
- 1999-04-22 YU YU64900A patent/YU64900A/sh unknown
- 1999-04-22 SK SK1608-2000A patent/SK16082000A3/sk unknown
- 1999-04-22 ID IDW20002196A patent/ID26704A/id unknown
- 1999-04-22 CN CNB998079553A patent/CN1170941C/zh not_active Expired - Fee Related
- 1999-04-22 HR HR20000736A patent/HRP20000736A2/hr not_active Application Discontinuation
- 1999-04-22 AU AU31634/99A patent/AU769124B2/en not_active Ceased
- 1999-04-22 AP APAP/P/2000/001982A patent/AP1329A/en active
- 1999-04-22 PL PL99343817A patent/PL343817A1/xx not_active Application Discontinuation
- 1999-04-22 UA UA2000116830A patent/UA72212C2/uk unknown
- 1999-04-22 TR TR2000/03182T patent/TR200003182T2/xx unknown
- 1999-04-22 EP EP99913528A patent/EP1076713A1/en not_active Withdrawn
- 1999-04-22 BR BR9910585-3A patent/BR9910585A/pt not_active IP Right Cessation
- 1999-04-22 WO PCT/IB1999/000733 patent/WO1999057293A1/en not_active Ceased
- 1999-04-22 NZ NZ507625A patent/NZ507625A/en unknown
- 1999-04-22 US US09/674,311 patent/US6534268B1/en not_active Expired - Fee Related
- 1999-04-22 KR KR1020007012054A patent/KR20010071193A/ko not_active Ceased
- 1999-04-22 EA EA200001130A patent/EA004509B1/ru not_active IP Right Cessation
- 1999-04-22 GE GEAP19995635A patent/GEP20033056B/en unknown
-
2000
- 2000-10-24 BG BG104883A patent/BG64780B1/bg unknown
- 2000-10-27 NO NO20005433A patent/NO20005433L/no not_active Application Discontinuation
- 2000-10-27 ZA ZA200006080A patent/ZA200006080B/xx unknown
-
2002
- 2002-10-03 US US10/263,788 patent/US20030040007A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AP1329A (en) | 2004-11-22 |
| AP2000001982A0 (en) | 2000-12-31 |
| HUP0102329A3 (en) | 2006-03-28 |
| NO20005433D0 (no) | 2000-10-27 |
| BR9910585A (pt) | 2001-01-09 |
| TR200003182T2 (tr) | 2001-02-21 |
| GEP20033056B (en) | 2003-08-25 |
| NO20005433L (no) | 2000-10-27 |
| EA200001130A1 (ru) | 2001-04-23 |
| EE200000627A (et) | 2002-02-15 |
| AU769124B2 (en) | 2004-01-15 |
| CN1170941C (zh) | 2004-10-13 |
| UA72212C2 (en) | 2005-02-15 |
| HUP0102329A2 (hu) | 2001-10-28 |
| US20030040007A1 (en) | 2003-02-27 |
| US6534268B1 (en) | 2003-03-18 |
| WO1999057293A1 (en) | 1999-11-11 |
| JPH11313675A (ja) | 1999-11-16 |
| EA004509B1 (ru) | 2004-04-29 |
| IL139100A0 (en) | 2001-11-25 |
| ID26704A (id) | 2001-02-01 |
| CA2326957A1 (en) | 1999-11-11 |
| AU3163499A (en) | 1999-11-23 |
| HRP20000736A2 (en) | 2001-10-31 |
| NZ507625A (en) | 2003-12-19 |
| KR20010071193A (ko) | 2001-07-28 |
| EP1076713A1 (en) | 2001-02-21 |
| BG104883A (en) | 2001-05-31 |
| YU64900A (sh) | 2003-10-31 |
| ZA200006080B (en) | 2001-10-29 |
| CN1307643A (zh) | 2001-08-08 |
| BG64780B1 (bg) | 2006-03-31 |
| PL343817A1 (en) | 2001-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Teufel et al. | Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes | |
| Villarreal et al. | Structure of human osteonectin based upon analysis of cDNA and genomic sequences | |
| US6534268B1 (en) | Human BMP-7 promoter and method for exploring bone-related substance by using the same | |
| WO1996038590A9 (en) | Methods and compositions for identifying osteogenic agents | |
| WO2002046364A2 (en) | Genes associated with mechanical stress, expression products therefrom, and uses thereof | |
| Taylor et al. | Identification of antisense transcripts of the chicken insulin-like growth factor-II gene | |
| US20040116671A1 (en) | Novel polypeptides and nucleic acids encoding same | |
| AU726918B2 (en) | TGFbeta signal transduction proteins, genes, and uses related thereto | |
| US6479259B1 (en) | Human peripheral nerve, tetrodotoxin-resistant sodium channel α-subunit polypeptide | |
| WO1997022697A9 (en) | TGFβ SIGNAL TRANSDUCTION PROTEINS, GENES, AND USES RELATED THERETO | |
| Shimuta et al. | Structure and expression of mitsugumin29 gene | |
| AU710551B2 (en) | Nucleic acid encoding a nervous tissue sodium channel | |
| US6475735B1 (en) | Human BMP-2 promoter and method for exploring bone-related substance by using the same | |
| CZ20004017A3 (cs) | Lidský BMP-7 promotor a způsob zjištění substancí ovlivňujících kost za použití tohoto promotoru | |
| MXPA00010413A (en) | Human bmp-7 promoter and method for exploring bone-related substance by using the same | |
| AU759569B2 (en) | Human BMP-4 promoter and method for exploring bone-related substance by using the same | |
| CZ20004016A3 (cs) | Lidský BMP-4 promotor a způsob pro výzkum substancí ovlivňujících kosti za použití tohoto promotoru | |
| MXPA00010405A (en) | Human bmp-4 promoter and method for exploring bone-related substance by using the same |